Apply for Grants

The Division of Cancer Treatment and Diagnosis funds a large portfolio of grants and contracts. Here we provide a listing of funding opportunities that are accepting applications. Please visit this page regularly for updates.

Important DCTD Grantsmanship Resources

Awaiting Receipt of Applications (ARAs) for Large Budget Grant Applications

Program Project (P01) Grant Development Guidance for Investigators Interested in DCTD Research Areas

Funding Opportunities through DCTD’s Programs

Visit the websites of DCTD's individual programs for more information on available funding opportunities.

Additional DCTD Notices of Funding Opportunity (NOFOs)
(listed by expiration date)
Title	Announcement Number	Expiration Date	Activity Code
Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Not Allowed)	PAR-22-090	January 8, 2025	R21
Exploratory/Developmental Bioengineering Research Grants (EBRG) (Clinical Trial Optional)	PAR-22-091	January 8, 2025	R21
Bioengineering Partnerships with Industry (U01 Clinical Trial Optional)	PAR-22-123	January 8, 2025	U01
Administrative Supplements to Support Cancer Disparity Collaborative Research (Clinical Trial Optional)	PAR-22-114	January 24, 2025	Admin Suppl
Cancer Tissue Engineering Collaborative: Enabling Biomimetic Tissue-Engineered Technologies for Cancer Research (R01 Clinical Trial Optional)	PAR-22-099	May 8, 2025	R01
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed)	PAR-22-086	May 8, 2025	R21
Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (Clinical Trial Not Allowed)	PAR-22-085	May 8, 2025	R01
Systematic Testing of Radionuclides in Preclinical Experiments (STRIPE) (Clinical Trial Not Allowed)	PAR-22-139	May 8, 2025	R01
Systematic Testing of Radionuclides in Preclinical Experiments (Clinical Trial Not Allowed)	PAR-22-140	May 8, 2025	R21
NCI Clinical and Translational Exploratory/Developmental Studies (Clinical Trial Optional)	PAR-22-216	July 2, 2025	R21
Imaging, biomarkers and digital pathomics for the early detection of premetastatic cancer and precancerous lesions associated with lethal phenotypes (Clinical Trial Optional)	PAR-22-131	September 8, 2025	R01
Bioengineering Research Grants (Clinical Trial Optional)	PAR-22-243	September 8, 2025	R01
Bioengineering Research Grants (Clinical Trial Not Allowed)	PAR-22-242	September 8, 2025	R01
Coinfection and Cancer (Clinical Trial Not Allowed)	PAR-23-056	November 17, 2025	R21
Innovative Research in Cancer Nanotechnology (IRCN; Clinical Trial Not Allowed)	PAR-23-246	May 5, 2026	R01
Assay Development and Screening for Discovery of Chemical Probes, Drugs or Immunomodulators (Clinical Trial Not Allowed)	PAR-23-264	September 8, 2026	R01
Academic-Industrial Partnerships (AIP) to Translate and Validate In Vivo Imaging Systems (Clinical Trials Optional)	PAR-23-259	January 8, 2027	R01
NCI's Investigator-Initiated Early Phase Clinical Trials for Cancer Treatment and Diagnosis (Clinical Trial Required)	PAR-24-085	January 8, 2027	R01
Notice of Special Interest (NOSI): Quantum Sensing Technologies in Biomedical Applications	NOT-EB-23-022	January 27, 2027	NOSI
Research Projects to Develop Oncoaging Models for Cancer Research	NOT-CA-23-092	July 31, 2027	NOSI
Specialized Programs of Research Excellence (SPOREs) in Cancer Health Disparities and Minority Health (CHD-MH) (U54 Clinical Trial Optional)	RFA-CA-24-020	September 27, 2024	U54